GlassScriptPhysician profile
Jennifer G Eaves
NPI 1356676340
$3,511.93
in general payments reported to CMS, 2019-2025
32 companies · $632 in 2025
The $632 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,006 · 2022: $629 · 2023: $664 · 2024: $581 · 2025: $632.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,878.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,877.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $618.81 | 2021-2025 | Dysport |
| Abbvie INC. | $542.33 | 2022-2025 | |
| Radius Health, INC. | $343.20 | 2021-2025 | Tymlos |
| Avanir Pharmaceuticals, INC. | $334.48 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $196.61 | 2021-2022 | |
| Pfizer INC. | $169.62 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $160.60 | 2021-2022 | |
| Collegium Pharmaceutical, INC. | $155.76 | 2021-2025 | Xtampza, Belbuca |
| Amgen INC. | $152.18 | 2021-2025 | Evenity, Prolia, Prolia |
| Otsuka America Pharmaceutical, INC. | $98.69 | 2023-2025 | Nuedexta |
| Ucb, INC. | $76.11 | 2023-2024 | Briviact |
| Amneal Pharmaceuticals LLC | $61.14 | 2023 | Lioresal (Baclofen), Lyvispah |
| Boston Scientific Corporation | $59.24 | 2024 | Wavewriter Alpha Prime 16 |
| Pacira Therapeutics, INC. | $54.24 | 2021 | |
| Nevro Corp. | $52.89 | 2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grt US Holding, INC. | $52.20 | 2021-2022 | |
| Saluda Medical Americas, INC. | $40.96 | 2025 | Evoke |
| Medtronic, INC. | $39.97 | 2021-2025 | Kyphon Express II Kyphopak Tray |
| Almatica Pharma LLC | $35.31 | 2022-2025 | Teriparatide |
| Ibsa Pharma INC. | $31.09 | 2023 | Tirosint, Licart |
| Nalu Medical, INC. | $24.51 | 2023 | Nalu Neurostimulation System |
| Ultragenyx Pharmaceutical INC. | $23.23 | 2021 | |
| Microtransponder, INC. | $21.20 | 2025 | |
| Merz Pharmaceuticals, LLC | $20.94 | 2025 | Xeomin |
| Abbott Laboratories | $20.83 | 2023 | Proclaim |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.53 | 2022 | |
| Tersera Therapeutics LLC | $20.41 | 2025 | Prialt |
| Vertex Pharmaceuticals Incorporated | $19.89 | 2025 | |
| Kyowa Kirin, INC. | $18.71 | 2024 | Crysvita |
| Dentsply Ih Ab | $18.09 | 2024 | Navina Rectal Catheter Set Regular |
| Alexion Pharmaceuticals, INC. | $15.09 | 2024 | Strensiq |
| Mdd US Operations, LLC | $13.07 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Eaves listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.